Podcasts about Pharma

HOUR 3: Why do we still allow Pharma ads? full 2089 Mon, 16 Mar 2026 21:00:00 +0000 npJ5KiwaZpbVzzAa1B5qtx8FPDiHK7HM news The Dana & Parks Podcast news HOUR 3: Why do we still allow Pharma ads? You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://player.amperwavepodcasting.com?feed-link=ht

From manufacturing data and AI adoption to workforce trends and the evolving role of women in industry, supply chain leaders are navigating a fast-changing landscape. In this episode of The Buzz, hosts Scott Luton and Karen Betancourt break down the latest global supply chain news and welcome Tracy Hyatt Bosman of Biggins Lacy Shapiro & Company to explore how economic signals, workforce dynamics, and site selection strategies are shaping the future of manufacturing and logistics. Buckle up and join us for this week's insights and conversations — welcome to The Buzz powered by Project44!This episode dives into the latest developments impacting global supply chains, including new data on U.S. manufacturing performance, the rapid rise of AI in factory operations, and the workforce dynamics influencing site selection and economic development. The conversation also highlights Women's History Month, explores real-world examples of supply chain and marketing alignment, and examines how emerging technologies and shifting economic signals are reshaping industry strategy.Tune in and learn:What the latest U.S. manufacturing data signals about jobs, tariffs, and production costsHow manufacturers are deploying AI to improve productivity, quality, and resilienceWhy workforce availability and skills remain the biggest factor in manufacturing site selectionThe myths and realities surrounding manufacturing careers and workforce shortagesKey economic insights from leading economists on the outlook for U.S. manufacturing and global tradeHow retailers like Target are investing in supply chain and fulfillment capabilities to compete in the omnichannel eraThe role of women's leadership in supply chain and manufacturing operationsWhy data centers are becoming a critical (and sometimes controversial) part of modern infrastructureWhether you're a supply chain leader, manufacturer, logistics professional, or industry enthusiast, this episode offers valuable perspective on the economic forces, workforce realities, and technology shifts shaping the future of supply chain. Tune in to gain practical insights and stay ahead of the trends influencing how the world moves goods, data, and innovation.Additional Links & Resources:Project 44: https://www.project44.com/With That Said: https://bit.ly/WTS-7-March-2026National Supply Chain Day: https://bit.ly/NSCD-2026American Supply Chain Summit: https://supplychainus.com/FritoLay Chip Challenge: https://bit.ly/Karen-FritoLay-Chip-ChallengeUS manufacturing activity steady, factory gate inflation surges: https://reut.rs/4roemtIU.S. payrolls unexpectedly fell by 92,000 in February; unemployment rate rises to 4.4%: https://cnb.cx/4bgHFseManufacturers are making progress with AI, but barriers remain: Cisco: https://bit.ly/State-of-AI-in-ManufacturingTarget readies next-day delivery for 20 more metros this spring: https://bit.ly/Target-Expands-Next-Day-DeliveryFox's Burton's Companies factory chief: “I was told being a woman would hold me back:” https://bit.ly/Women-In-ManufacturingDecision44 Event: https://www.project44.com/events/decision44/The Executives'​ Club of Chicago's Annual Economic Outlook 2026: https://www.linkedin.com/posts/traceyhyattbosman_before-it-gets-too-far-in-the-rearview-mirror-activity-7418784479105691649-Azng/Connect with Tracey on LinkedIn: https://www.linkedin.com/in/traceyhyattbosman/Connect with Karen on LinkedIn: https://www.linkedin.com/in/karendbetancourt/Learn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkSupply Chain Now en Espanol WEBINAR- Visibilidad estrategica en Pharma: control, cumplimiento y resiliencia en entornos de alto riesgo: https://bit.ly/4rku7lCWEBINAR- Talent Management Playbook for Supply Chain Leaders: https://bit.ly/4uc2OfBWEBINAR- From Workforce Planning to Hourly Performance Management: How GEODIS Americas Turned Labor Productivity into a Growth Engine: https://bit.ly/4blRfKpWEBINAR- Ahead of Disruption: How AI-First Design Builds Supply Chain Resilience — and Transforms the Teams Behind It: https://bit.ly/4ldRn3bThis episode is hosted by Scott Luton and Karen Betancourt, and produced by Trisha Cordes, Joshua Miranda, and Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/buzz-ai-hits-factory-floor-1557

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Joerg Ahlgrimm, CEO SK pharmteco.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering:   His journey from East Germany to leading global manufacturing organisations. How building and integrating acquired CDMO relationships ultimately led him to Lonza, where he helped scale the manufacturing network from fifteen to thirty five sites worldwide. What he learned about the “sticky” nature of the CDMO business, and the unforgiving reality of being a CDMO partner when execution does not go to plan. The leap from the scale and structure of Lonza in Basel to becoming employee number four at a CDMO start up in Philadelphia. Why his vision for a small molecule CDMO is to be easy to work with and present across the key global manufacturing regions. Why, despite the rise of blockbuster GLP one therapies, he believes the future lies in small volume, highly targeted, and complex to manufacture personalised medicines.   Joerg Ahlgrimm is a global operations and supply chain executive with more than 25 years of leadership experience across the biotech, pharmaceutical, vaccines, and medical device industries. As CEO of SK pharmteco, he leads the company's strategic growth and operational excellence across its global manufacturing network.   Prior to SK pharmteco, Joerg served as Head of Global Operations, Pharma and Biotech at Lonza AG, where he oversaw 37 sites worldwide. Earlier, he led the manufacturing network for Baxter Bioscience/Baxalta, managing a broad global footprint and extensive CMO operations.   Driven by a passion for advancing patient care, Joerg is recognized for building high-performing teams and navigating complex global supply chains. He was recently appointed to the inaugural Strategic Advisory Board of BioPhorum, joining senior industry leaders to help shape the future of pharmaceutical manufacturing and supply chain resilience.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The following article of the Entrepreneurs industry is: “Mexico's Strategic Growth in Pharma and Medical Nearshoring” by Deyanira Chiñas, Director Comercial, T5DC. (AA1113)

Global supply chains are navigating an era marked by evolving challenges and opportunities. As technological advancements such as AI continue to reshape the landscape, leaders must adapt to the constant pressures of global uncertainty.In this episode of Supply Chain Now, Scott Luton is joined by Tony Zuazo, Interim CEO of the Community Resource Center, to explore the intersection of people, process, and technology in today's supply chain environment. Tony shares insights from his extensive experience leading supply chains at Dollar General and his current work in nonprofit leadership. Together, they discuss the critical role of innovation in supply chain management, the growing significance of automation and AI, and the importance of adapting processes to meet both short-term needs and long-term goals.Scott and Tony also touch on the complexities of decision-making in global supply chains, the balance between technology and human-driven processes, and the need for clear communication in change management. The episode concludes with advice for leaders on how to manage uncertainty, drive efficiency, and keep people at the heart of successful supply chain operations.Jump into the conversation:(00:00) Intro(01:42) Tony Zuazo's background and supply chain leadership at Dollar General(07:35) Retail supply chain's evolution over the past decade(08:16) Shifts in technology: automation and AI(10:24) Unchanging global pressures in the supply chain(11:18) Importance of micro decisions in operations(13:52) Key non-negotiables at Dollar General(16:49) Overengineering vs. oversimplifying technology solutions(20:07) The importance of overcommunication in leadership(23:20) CRC's mission: hygiene and security(26:33) Ways to support the Community Resource Center(30:15) Leadership lessons: people, process, and technology(32:49) Standardizing processes with room for flexibilityAdditional Links & Resources:Connect with Tony Zuazo: https://www.linkedin.com/in/tonyzuazo/Learn more about the Community Resource Center: http://www.crcmidtn.orgLearn more about our hosts: https://supplychainnow.com/aboutLearn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkSupply Chain Now en Espanol WEBINAR- Visibilidad estrategica en Pharma: control, cumplimiento y resiliencia en entornos de alto riesgo: https://bit.ly/4rku7lCWEBINAR- Talent Management Playbook for Supply Chain Leaders: https://bit.ly/4uc2OfBWEBINAR- From Months to Days: How AI-Speed Supply Chain Design Is Breaking Traditional Org Models—And Talent Too: https://bit.ly/4ldRn3bThis episode was hosted by Scott Luton and produced by Trisha Cordes, Joshua Miranda, and Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/store-shelves-commnity-impact-journey-1556

S5:E219 David interviews Scott Pancoast, the Executive Chairman at Atticus Pharma, a spinout from Zylo Pharma where Scott is CEO. Atticus has 2 drug candidates from their Immunodermatology Platform and Scott updates listeners on the most recent developments at Atticus as they approach a liquidity event in the next few years. (recorded 2.18.26)Follow David on X at https://x.com/DGRollingSouth Connect On LinkedIn with David at https://www.linkedin.com/in/davidgrisell/ Follow Paul on X at https://x.com/PalmettoAngel Connect On LinkedIn with Paul at https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com.

What if a drug could kill cancer cells broadly, spare the immune system and then train it to keep fighting, without triggering resistance? That's the promise behind the ELANE pathway, a mechanism discovered not from a hypothesis but from studying fundamental biology in patients. In this episode of the In Vivo Podcast, Court Turner, CEO and co-founder of Onchilles Pharma, and Lev Becker, CSO and scientific founder, discuss how a neutrophil elastase-based mechanism is being translated into N17350, a first-in-class intratumoral agent targeting solid tumours including head and neck, skin and breast cancers. With $40m raised, GMP manufacturing of thousands of clinical doses completed, a US IND approved, and a first-in-human study underway in Australia, Onchilles is moving from "stubborn optimism" to clinical execution. Court and Lev discuss the dual mechanism that sets N17350 apart from both traditional chemotherapy and immunotherapy, why histone H1 functions as a universal tumour vulnerability rather than a conventional biomarker, and how they're thinking about combinations, partnering and the eventual value story for payers.

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mark Martin, managing director and global head of pharma services and technology at Houlihan Lokey, discusses M&A momentum and investor sentiment in pharma services.

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Bonefrog https://BonefrogCoffee.com/ToddGet the new limited release, The Sisterhood, created to honor the extraordinary women behind the heroes. Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeIf you can't practice tough love, you don't really love. Let's practice tough love and examine why Mike Pence, and establishment Republicans like this who I am calling “Trump 2.0”.Episode Links:Mike Pence loves him some war with Iran BREAKING: Senate Leader John Thune confirms HE'S FORCING A VOTE on the SAVE America Act, he will put Democrats ON THE RECORD opposing the 85-15 issue The Republican Party is protecting Ilhan Omar from accountability. Rep Nancy Mace “I tried to subpoena her immigration records, her brother husband's immigration records, and IT WAS REPUBLICANS that killed my motion” It's a Uniparty. One Big Club.URGENT: Big Pharma wins again; Dr. Vinay Prasad is out as the FDA's chief medical's officer. Not coincidentally, stocks of drug companies are soaring.TRUMP: “You gotta lighten up on this, they might have come into our country illegally but they're good people and they're cheap workers. They're working now on farms, in luncheonettes and hotels. We're just focused on getting the murderers out.” So much for mass deportations.Trump: We'll bring in any Iranian refugees that aid the U.S Military! Trump complained about the Afghan INVADERS and now is doing the same thing. This is how we got invaded with people from the Middle East.HOMELAND: Trump's new pick for Secretary of Homeland recently voted to ALLOW "Refugee" Welfare Programs to continue to be funded at Biden-era levels. Mullin also comforted & HUGGED the cop who shot Ashli Babbitt:  "He was distraught. I gave him a hug & said 'you did what you had to do.'" He also claimed Republican Senators were too "emotional" over Jan 6 to confirm Trump's pick Ed Martin for DC Prosecutor.Rep. Brian Mast: “Let's talk about Rep. Mace's resolution. Victims deserve protection. Witnesses deserve confidentiality. I voted to ensure survivors aren't forced to deal with the fallout of the public release of their sensitive information. I voted to send the resolution to the Ethics Committee so that it can be amended to adequately protect those who've done the brave thing and come forward.”Rep Anna Paulina Luna comes out and says it. She says the American People hate Congress for how corrupt they are. After both parties blocked disclosing slush funds using tax dollars to pay off their sexual assault charges, she loses it. “That's why the American people hate us”

Global supply chains are at an inflection point as geopolitical uncertainty collides with rapid AI advancement and rising performance expectations. Leaders must decide when to invest, where to modernize, and how to stay ahead.In this episode of Supply Chain Now, Scott Luton is joined by Mike Griswold, Vice President Analyst at Gartner, to reflect on insights from Manifest 2026 and the evolving role of supply chain leadership. Together, they explore practical AI adoption, the growing importance of augmentation over automation, and how supply chains are stepping into more strategic, decision-shaping roles.Scott and Mike discuss the shift from AI experimentation to real-world use cases that solve specific business problems. They emphasize the importance of integrating technology with strong processes, particularly in Sales and Operations Planning, and maintaining clarity between planning and execution. The conversation concludes with perspectives on investment timing, competitive advantage, and how leaders can confidently navigate uncertainty while building stronger, more resilient supply chains.Jump into the conversation:(00:00) Intro(02:26) Coaching championship and basketball trivia showdown(06:20) Sports nostalgia and shifting into supply chain mode(07:30) Manifest 2026 and five major supply chain technology themes(09:29) Moving from AI theater to real-world use cases(13:16) Investment hesitation and navigating market uncertainty(17:03) “We never lacked data,” and the rise of new analysis paralysis(21:55) Using frameworks and knowing when enough insight is enough(26:47) Why S&OP struggles with executive support(29:56) S&OP versus S&OE and avoiding tactical drift(31:22) How the supply chain became a strategic decision shaper(35:42) Why the Gartner Supply Chain Symposium is a must-attend event(38:19) How to connect with Mike and a deeds not words challengeAdditional Links & Resources:Connect with Mike Griswold: https://www.linkedin.com/in/mike-griswold-6a68922/Connect with Mike through email: mike.griswold@gartner.comLearn more about Gartner: https://www.gartner.com/enLearn more about our hosts: https://supplychainnow.com/aboutLearn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkSupply Chain Now en Espanol WEBINAR- Visibilidad estrategica en Pharma: control, cumplimiento y resiliencia en entornos de alto riesgo: https://bit.ly/4rku7lCWEBINAR- Talent Management Playbook for Supply Chain Leaders: https://bit.ly/4uc2OfBWEBINAR- From Months to Days: How AI-Speed Supply Chain Design Is Breaking Traditional Org Models—And Talent Too: https://bit.ly/4ldRn3bThis episode was hosted by Scott Luton and produced by Trisha Cordes, Joshua Miranda, and Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/how-ai-transforming-supply-chain-decision-making-2026-1555

Can a clinician really thrive in the high-stakes world of pharmaceutical sales?In this episode of Medical Sales U, I sit down with Randy Rhodes, a former Nurse Practitioner at the Cleveland Clinic who successfully transitioned into Oncology Sales. Randy pulls back the curtain on why he left the bedside, the "identity crisis" clinicians face when moving to sales, and the exact strategy he used to land a role at a top pharma company.Whether you are a nurse practitioner, RN, or pharmacist looking to break into the industry, this deep dive provides the tactical roadmap you need to bridge the gap between clinical expertise and commercial success.WHAT YOU'LL LEARN IN THIS EPISODE:* The "Business of Nursing": Why Randy's business degree and clinical background became his "unfair advantage."* The MSL vs. Sales Debate: Why Randy pivoted from the Medical Science Liaison path to the commercial side.* The 4:54 AM Mindset: How a disciplined routine (and CrossFit!) fuels a successful sales territory.* Overcoming the "Salesperson" Stigma: How to stay patient-centric while hitting your quota.* Interview Secrets: The specific questions Randy wasn't prepared for and how you can avoid his mistakes. TIMESTAMPS:0:00 - Intro: Meet Randy Rhodes, NP turned Oncology Pro02:15 - The Louisiana Connection: From Business to Nursing05:30 - Life at the Cleveland Clinic: Bone Marrow Transplant Expertise09:45 - Making the Jump: Why Pharma?13:10 - The MSL Interview Nightmare: Learning the Hard Way18:40 - Reframing "Sales": It's About the Patient22:15 - Landing the Job: The 4-Round Interview Process26:30 - A Day in the Life: Sunday Planning & Territory Hustle32:00 - Staying Motivated When Doctors Say "No"38:45 - Leadership & Advice for Aspiring Reps42:10 - The Power of Feedback: Why Every "No" is a "Not Yet"

For decades, Africa has depended on imported medicines for diseases that disproportionately affect its people. But what happens when a country decides to manufacture its own? In this episode of The Long Form Podcast, economic strategist Michael Fairbanks explains the ambitious vision behind Akagera Medicines, a Rwanda-linked biotech company developing treatments for drug-resistant tuberculosis. Backed by Rwanda's national pension fund, this project raises difficult questions about pharmaceutical sovereignty, global health inequality, African industrial policy, and the risks of building a biotech industry from scratch. Can Africa truly compete with global pharmaceutical giants? And what happens if the bet fails? This conversation explores the intersection of science, capital, geopolitics, and the future of African healthcare innovation.Sponsors:Threat Informat - https://threatinformant.io/.                                                    Akagera Medicines- https://www.akageramedicines.com/ Join our Patreon to enjoy ad-free viewing https://www.patreon.com/cw/TheLongFormPod or support us via our MTN Mobile Money Code 95462 or directly to our phone number: +250795462739 Visit Sanny Ntayombya's Official Website: https://sannyntayombya.com Produced by LF Media

In this episode of SCW for Pharma, Evren Ozkaya welcomes Tim Tyson, Chairman and CEO of TriRx Pharmaceutical Services.The conversation begins with Tim's professional journey in the pharmaceutical industry. Starting his career in operations and manufacturing, he worked closely with major pharmaceutical companies before rising to executive leadership roles at GSK, where he served as the president of the Global Manufacturing and Supply Division. Tim reflects on what continues to resonate with him about the pharmaceutical industry: the opportunity to contribute to life-altering and life-saving medicines that have a meaningful impact on patients around the world.Evren and Tim then compare the pharma services (CDMO) industry with consumer goods manufacturing. While the industries differ in many ways, Tim highlights a surprising similarity: both operate with relatively tight margins, making operational efficiency and continuous improvement essential for long-term competitiveness.The discussion then shifts to Tim's perspective on the Contract Development and Manufacturing Organization (CDMO) business model. Tim explains that outsourcing specialized manufacturing capabilities allows pharmaceutical companies to increase efficiency and reduce costs, particularly when CDMOs can achieve higher capacity utilization across their facilities. He emphasizes that making the right investments in facilities and technologies is essential for serving both human and animal health markets effectively.A major challenge across the industry, however, is low capacity utilization. Tim notes that average utilization rates can be as low as 24%, while a sustainable business typically requires at least 40–45%. Although many CDMOs target utilization rates closer to 70%, regulatory constraints and market dynamics often make this difficult to achieve. According to Tim, improving utilization and operational efficiency will be critical for the long-term sustainability of pharmaceutical manufacturing.Evren and Tim also discuss the recent wave of investments in new pharmaceutical factories, particularly in the United States. Tim argues that from both an engineering and financial perspective, building new facilities may not always be the most rational solution when significant unused capacity already exists. Instead, he advocates for modernizing existing facilities, adopting new technologies, and improving operational performance to unlock value from current infrastructure. At the same time, the industry is experiencing growing regionalization, with reshoring trends emerging not only in the U.S. but also across Europe, China, and India.The conversation then turns to the role of visibility and digitalization in pharmaceutical manufacturing. Tim emphasizes that successful CDMOs must build strong customer relationships based on trust and consistently deliver products that meet regulatory standards and arrive on time and in full. Achieving this requires moving beyond fragmented spreadsheets toward digital factories that provide real-time operational visibility. With better data and transparency, organizations can identify hidden inefficiencies, drive continuous improvement, and maximize operational performance.Finally, the discussion addresses the growing interest in AI across the pharmaceutical sector. Tim believes predictive tools can provide meaningful value in manufacturing environments, particularly for identifying improvement opportunities and supporting data-driven decision-making. However, he stresses that organizations must first establish strong data foundations before.

Dans cet épisode de Cheminements enregistré en public, nous explorons une aventure collective qui fait bouger les lignes de la prévention solaire. Comment passer des discours médicaux classiques à une communication qui "passe crème" auprès des jeunes ? À travers trois projets concrets. Du programme Student Voices au jeu de 7 familles pédagogique, jusqu'à l'outil MySun Experience, nos invitées dévoilent les coulisses d'une collaboration inédite entre une association de patients et un laboratoire dermatologique. Un échange riche sur l'importance de la co-construction pour transformer des messages de santé en véritables réflexes de vie.Les intervenantes :Pascale Benaksas : présidente de l'association France Assos Cancer et Peau, patiente engagée pour le dépistage précoce.Céline Decarpigny : chef de projet expérience patient au sein du Groupe Pierre Fabre.Catherine Baissac : docteur en pharmacie et responsable expérience patient (Patient Advocacy) chez Pierre Fabre.Les sujets abordés dans l'épisode :Les nouveaux codes de communication : pourquoi parler de vieillissement cutané et d'esthétique touche plus les jeunes que le discours sur le cancer.L'effet "daronne" : comprendre les freins psychologiques et sociaux à l'application de la crème solaire entre amis.Le danger des cabines UV : le combat pour l'interdiction des "machines à cancer" en France.Le jeu comme outil de soin : comment un jeu de 7 familles peut transformer les enfants en ambassadeurs de la prévention.L'algorithme du vieillissement : présentation de MySun Experience, l'outil qui calcule l'impact réel de vos habitudes solaires sur votre peau dans 15 ans.Crédits :Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode à été enregistré durant la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui a eu lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que d'autres épisodes exclusifs du podcast Cheminements ont été enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui sont venus raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for a powerful episode exploring mental health in the workplace and practical support strategies with crisis mental health expert Jessi Beyer. In this compelling conversation, Jessi unpacks the realities of mental health challenges, particularly in high-risk and safety-critical environments. Backed by eye-opening statistics and real-world stories, she explains how these challenges directly impact performance, culture, and overall workplace safety. Jessi emphasizes the importance of building a true culture of care grounded in trust, psychological safety, and meaningful peer support. She also introduces her impactful L.I.F.E. framework for suicide prevention, offering clear, practical guidance to help leaders and teams take meaningful steps toward prevention. If you are ready to move your workplace from crisis response to proactive care, this episode delivers practical strategies to strengthen mental health and ensure every team member feels seen, supported, and valued. Tune in. This is a conversation that truly matters! About the Guest: Jessi Beyer, MHP, is an award-winning international speaker, #1 best-selling author of How To Heal, and a crisis mental health professional embedded with law enforcement and Region 1 SWAT in Snohomish County, Washington. Named the 2025 Best International Mental Health Speaker by Global Health and Pharma, she has been featured in over 200 media outlets and has spoken to thousands of people worldwide. Jessi holds master's degrees in critical psychology, human services, and military psychology, with a focus on trauma, crisis intervention, and terrorism. She is deeply passionate about supporting military and first responder mental health, drawing from both her professional experience and personal ties to those who serve. For more information: https://jessibeyerinternational.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

What does it take to lead supply chain in a world where disruption is constant?In this episode, host Karin Bursa welcomes a powerhouse panel of supply chain leaders for a candid conversation on supply chain leadership in the never-normal world and what it takes to connect strategy to execution. Together, Eduardo Adame of 3M, Douglas Guilherme of The Hershey Company, Cory Knox of Procter & Gamble, and Shea Nesseler of Danone share the career moments that shaped how they lead, from navigating Covid-era realities to guiding teams through high-stakes change and uncertainty.You'll hear real-world insights on building resilient supply chains, investing in the right capabilities, preparing teams for AI-enabled planning, and leading with empathy during moments of disruption.Jump into the conversation:(00:00) Intro(02:27) Meet today's panel of supply chain leaders(05:41) Career moments that shaped their leadership(14:17) AI plus people, the real advantage(22:46) The toughest challenges supply chain teams face now(24:52) Strategy starts with strong partnerships(25:26) Why external focus makes better decisions(26:29) Quality decisions beat fast decisions(28:00) Building resilience through consistency(29:18) Modernizing planning with smarter systems(30:55) Developing talent for what's next(31:44) Advice they would give their younger selvesAdditional Links & Resources:Connect with Karin Bursa: https://www.linkedin.com/in/karinbursa Connect with Douglas Guilherme: https://www.linkedin.com/in/douglasguilherme/Learn more about The Hershey Company: https://www.thehersheycompany.com/Connect with Cory Knox: www.linkedin.com/in/cory-knox-7806986Learn more about Procter & Gamble: https://www.pg.com/Connect with Shea Nesseler: https://www.linkedin.com/in/shea-nesseler/Learn more about Danone: https://www.danone.com/Connect with Eduardo Adame: https://www.linkedin.com/in/eduardo-adame-92192427/Learn more about 3M: https://www.3m.com/Learn more about our hosts: https://supplychainnow.com/aboutLearn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkSupply Chain Now en Espanol WEBINAR- Visibilidad estrategica en Pharma: control, cumplimiento y resiliencia en entornos de alto riesgo: https://bit.ly/4rku7lCThis episode was hosted by Karin Bursa and produced by Trisha Cordes, Joshua Miranda, and Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/supply-chain-leadership-never-normal-where-strategy-meets-execution-1553

Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights the practical shifts required to get there — from cross‑functional adoption and workflow‑embedded insights to attribution modeling, efficiency gains, and focused pilots that prove value quickly. This episode is sponsored by ODAIA. Learn how brands work with Emerj and other Emerj Media options at emerj.com/partner. Want to share your AI adoption story with executive peers? Click emerj.com/expert for more information and to be a potential future guest on the 'AI in Business' podcast!

This is for the woman who's aiming for a promotion (or a bigger external role) and keeps thinking, If I could just get that title, everything would feel different.Today we are going beyond the title to talk about the messy middle, what drives advancement and the critical part needed to reach your advancement goal. When you don't understand your deeper “why,” you can end up pushing for something that isn't actually the solution… or finally getting it and realizing it feels hollow.In this episode, you'll learn:Why I ask “why” first when someone says they want a promotion title—and the common answers that quietly stall progressThe three deeper drivers I hear most often and what each one actually requires in Pharma/BiotechWhy “I earned it” and “I work hard” rarely works as a promotion strategy in complex organizationsGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Salesforce Solution Engineers are like general contractors, according to David Young, who leads a team of them at Salesforce. They need skills like carpentry and framing and plumbing but also know when to stop and call in an expert. In the Salesforce world this might be knowing when to bring in a service cloud or an Agentforce expert. They need to know enough to see the business challenge and know who to tap for help.I have always advocated that ISVs spend time thinking about SEs, even moreso than AEs, because the math just maths. AEs have shorter tenure at Salesforce than SEs. AEs have more ISVs reaching out to them than SEs. And AEs might have 1 or 5 accounts in the enterprise, but SEs often support multiple AEs which just multiplies the number of accounts that a single session with you could reach. We cover a bunch of topics, but here is a summary:What does an SE at Salesforce do?What type of person is an SE at Salesforce?How does David decide which ISVs to engage with?How do SEs learn about new ISVs?What are some dos and don'ts when ISVs are engaging with SEs? Shoutout to Myroad.io, who is doing a great job of it.What should an ISV know/do before they are “ready” to engage with Salesforce SEs?How do SEs work with SDOs and IDOs to demo Salesforce's tech?Thanks again to David for sharing with the community!And thank you to Sam Yarborough for the intro. If any of you have a Salesforce AE or RVP that might give us the real talk, it'd be great to get their pov. This episode is brought to you by ISVApp. ISVapp the usage analytics platform built specifically for Salesforce ISV and OEM applications.ISVapp is your central toolbox for reducing churn, increasing renewals, uncovering upsell opportunities, and closing more deals. 

Join Dominique Surinx, CEO and President of Ansana, for a high-level discussion on the digital transformation of the healthcare industry. With 20 years of experience in the corporate pharmaceutical world and a decade as a successful entrepreneur, Dominique brings a rare perspective to the table. In this episode, we explore how AI is moving from a back-office tool to a frontline catalyst for innovation, improving patient outcomes and accelerating the development of life-saving treatments.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the pharmaceutical and biotech industries. The landscape continues to evolve with scientific breakthroughs, regulatory hurdles, and strategic alliances that have profound implications for drug development and patient care.Let's begin with Novo Nordisk's substantial investment of $500 million into an Ireland-based plant. This move reflects the ongoing demand for obesity treatments like Wegovy, a GLP-1 receptor agonist known for its efficacy in diabetes and weight management. The expansion aims to enhance production capabilities, particularly for markets outside the US, highlighting the global demand for such therapies. Recent studies in rodents suggest that GLP-1 medications may also support heart attack recovery by relaxing blood vessels, indicating broader cardiovascular benefits. This illustrates the multifaceted potential of GLP-1 receptor agonists beyond their primary indications.Turning to regulatory developments, the FDA has issued complete response letters to AstraZeneca and GSK, citing deficiencies in their data submissions. The feedback questions the data integrity of AstraZeneca's Saphnelo and the efficacy of GSK's Exdensur. These letters emphasize the importance of robust clinical evidence for achieving regulatory approval, underscoring the FDA's stringent standards. Such regulatory scrutiny highlights the necessity for pharmaceutical companies to ensure comprehensive and transparent data presentation.In strategic maneuvers within the industry, Esperion Therapeutics has acquired Corstasis Therapeutics for over $75 million, bringing the newly FDA-approved nasal spray Enbumyst into its portfolio. This acquisition illustrates ongoing consolidation trends aimed at diversifying product offerings and strengthening market positions in an increasingly competitive landscape.Meanwhile, DISC Medicine's decision to lay off 20% of its workforce following the FDA's rejection of a rare disease drug candidate underscores the volatility and risk inherent in drug development. This highlights the financial and operational challenges biotechs face when navigating complex regulatory pathways.Novo Nordisk and BioMarin have received FDA label expansions, allowing them to reach broader patient populations or offer additional therapeutic indications. Such expansions are crucial for enhancing treatment access and driving company growth. However, these advancements also reflect the challenges companies face in meeting evolving regulatory expectations while striving to expand their market footprint.Geopolitical tensions impact the industry as well, with companies closely monitoring employee safety and supply chain stability amid conflicts in regions like the Middle East. This situation highlights the vulnerabilities of global operations and underscores the need for robust contingency planning to maintain medicine access during crises.On the innovation front, Kyowa Kirin has discontinued its late-stage autoimmune disease program following cancer concerns linked to its anti-OX40 monoclonal antibody. This decision reflects the complexities of balancing innovative research with patient safety considerations. The discontinuation followed new cancer cases among participants receiving an anti-OX40 monoclonal antibody treatment, emphasizing the critical need for robust safety monitoring throughout the development process.Theravance Biopharma's substantial downsizing reflects similar challenges after a failed phase 3 trial for a blood pressure disorder drug led to significant corporate restructuring. This highlights how clinical setbacks can profoundly impact corporate strategy and employee livelihoods, serving as cautionary tales about resource investments required inSupport the show

Regulations governing AI are more than likely on their way – but a lot of unknowns remain. Some might say too many unknowns remain, which isn't great for business. While clear, comprehensive regulations for AI are widely expected – and requested – by nearly every sector of the economy, there's plenty we don't know.  That said, business leaders can not and will not operate in the dark.  Executives in our orbit, whether leading drug manufacturers, major medical marketing agencies or health media companies, require at least a sense of what's on the horizon. This week, pharma editor Lecia Bushak speaks with Darshan Kulkarni, a pharma regulatory consultant and founding partner at his namesake law firm. Their conversation explores the potential of new laws and regulations around AI use cases in medical marketing, such as digital avatars. And for our Trends segment, we're talking about Bayer's lawsuit against Johnson & Johnson for its marketing practices around a prostate cancer drug. Plus, we are graced with a dramatic reading of Steve Madden's satirical FDA Untitled Letter to ESPN over their faux pharma ad for March Madness.   Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

National Director of Account Management of Sales of IQVIA's Chris Hankey discusses biobanking, digital transformation, and better health outcomes for patients. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

Stephen Grootes speaks to Sean Capazorio, Aspen Group Chief Financial Officer about the group’s encouraging interim results and the strategic shifts shaping its next phase of growth. Driven by strong momentum in Commercial Pharmaceuticals and decisive action to reshape its Manufacturing platform, Aspen delivered steady execution in what it describes as a transitional first half, despite once-off restructuring costs and the absence of prior mRNA contract contributions. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Pharma ads, biotech IPOs, $1M longevity programs, oh my!This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.We cover:Why pharma ads are surging and the growing push for restrictions on D2C drug advertisingHims & Hers' $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugsThe return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discoveryVaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter fundingTrumpRx's “most favored nation” drug pricing approach, and what one STAT analysis foundBryan Johnson's $1M per year “Immortals” longevity program—Show notes:Should drug companies be advertising to consumers? (The New York Times) Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)Vaccine Makers Curtail Research and Cut Jobs (The New York Times) TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)Bryan Johnson's Immortals: $1M to try longevity regimen (Axios) —"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she's written a book on how she went about it." - The WSJMassively Better Healthcare is out now!—Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here. —

How do you go from fashion merchandising to the "cream of the crop" in Oncology sales? Marilu Restrepo, an Executive Sales Specialist in Hematology/Oncology, shares her raw, personal journey—from a Division I athlete to losing her cousin to breast cancer—and how that tragedy transformed into a high-stakes career helping cancer patients.Marilu's insights on "Selling with Passion," leveraging AI for pre-call planning, and overcoming rejection are essential listening.TOPICS:* Selling with Passion: Why your "Why" helps you overcome any clinical objection.* The Inside Sales Foundation: Developing the confidence to handle high-volume rejection.* The Oncology Shift: How to manage complex territories and collaborate with clinical teams.* AI Productivity: How Marilu uses ChatGPT to brainstorm probing questions and stay organized.CHAPTERS:00:00 – Meet Marilu Restrepo: From D1 Track to Executive Sales.02:15 – The Turning Point: How a family tragedy changed her career path.04:30 – Inside Sales 101: Why the "grind on the phone" is a lost art.06:55 – Overcoming Rejection: Applying to 40+ jobs and winning.09:20 – The "Fire" of the OR: Navigating high-intensity Cardiac Device sales.12:10 – Making the Leap: Breaking into Oncology and Prostate Cancer.15:00 – Working with the Team: Collaborating with MSLs and Nurse Educators.17:45 – The Modern Rep: Using AI & ChatGPT for elite pre-call planning.20:15 – Life Outside the Lab: Balance, Motherhood, and... the best Italian in Ohio?23:10 – Final Advice: Why your "Why" is your greatest sales tool.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

Dans ce nouvel épisode de Cheminements, enregistré en live lors de la Journée Patient & Pharma, nous explorons les coulisses d'une collaboration fructueuse entre le monde associatif et l'industrie pharmaceutique. Loin des postures de principe, nos invitées nous expliquent comment elles ont bâti une relation durable pour répondre aux enjeux critiques des déficits immunitaires primitifs (DIP). De la lutte contre l'errance diagnostique à la sécurisation de l'accès aux immunoglobulines, découvrez comment l'écoute du "savoir expérientiel" des patients transforme concrètement le développement des solutions de santé et influence les politiques publiques.Les intervenants :Virginie Milière : déléguée générale de l'association IRIS (représentation et accompagnement des personnes atteintes de déficits immunitaires primitifs).Tania Aydenian : directrice du département Value-Based Partnerships chez Takeda.Les sujets abordés dans l'épisode :La genèse et l'évolution de la relation de confiance entre IRIS et Takeda malgré les restructurations industrielles.Les défis spécifiques des DIP : une errance diagnostique de 6 ans en moyenne et une dépendance aux médicaments dérivés du plasma.La différence entre un simple changement de conditionnement et une réelle innovation améliorant la qualité de vie des patients.L'importance de la transparence : savoir se dire les choses, même quand elles sont difficiles, pour avancer vers un objectif commun.La création de l'Alliance Plasma : un plaidoyer unique regroupant industriels et associations pour peser sur les décisions publiques.L'engagement humain au-delà du cadre professionnel, illustré par la participation des collaborateurs aux événements associatifs.Crédits :Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode à été enregistré durant la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui a eu lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que d'autres épisodes exclusifs du podcast Cheminements ont été enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui sont venus raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Brigham Buhler is a healthcare entrepreneur, founder and CEO of Ways2Well, and co-founder of ReviveRx Pharmacy. https://ways2well.com EPISODE LINKS https://www.instagram.com/brigham.buhler https://ways2well.com SPONSORS https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Becoming the first drug rep for Cialis 04:47 - The primary care problem in America 07:20 - Why you should self-pay prescription drugs 12:10 - The dirty secret of anti-depressants 16:13 - The prescription drug incentive program 21:27 - 5 insurance companies cover 90% of Americans 23:31 - The Pharmacy Benefit Managers scam 28:48 - Think of health insurance like car insurance 31:27 - The #1 mistake we're making with our health 34:26 - The testosterone myth 38:51 - Why it costs $250M to bring a drug to market 44:32 - Why health insurance keeps you in the dark 45:31 - How we're fixing problems in healthcare 49:58 - How Brigham ended up on JRE 53:17 - Lobbying against peptides with the FDA 01:00:34 - Why "FDA-approved" products aren't always safe 01:06:08 - The "problem" with peptides 01:08:02 - The origin of the opioid crisis 01:11:48 - Pediatrician's vaccine schedules 01:17:55 - Changes in child vaccine requirements 01:21:41 - How fast medical knowledge becomes antiquated 01:25:21 - Why RFK backed down on vaccines 01:29:49 - Importance of flipping the food pyramid 01:33:44 - Combining IGF + GLP-1 drugs 01:36:50 - Jelly Roll's weight transformation 01:44:19 - Small wins = huge progress 01:47:44 - Brigham's efforts in the MAHA movement 01:54:15 - FDA's response to MAHA 02:00:01 - Protecting healthcare from future administrations 02:06:55 - American healthcare vs. other countries 02:08:44 - Food ingredients in US vs. Europe 02:15:15 - New stem cell treatments 02:17:06 - Why stem cells were banned in America 02:22:17 - New Japanese stem cell discovery 02:28:33 - Early anecdotal results from stem cell therapy 02:31:51 - We can create real-life X-Men 02:36:24 - Psychedelics & super soldiers 02:42:26 - The MINDS project (psychedelic problem-solving) Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering:   How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing. The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles. Lessons from hundreds of deals, and why the best investments are often the most complex and hardest won. Why running from ego and listening obsessively to clients is one of the most underrated advantages in private equity. Why private equity has become increasingly commoditised, and why Banks believes momentum is building and sentiment is turning positive heading into 2026. As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.   For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks' initial investment in King Pharmaceuticals in the late 1990's. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.   While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children's Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO). Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Meet Kim Jablonski, the former Chief Compliance and Ethics Officer at Bristol Myers Squibb, where she navigated the complex world of pharmaceutical ethics. With nearly her entire career at this global giant, Kim juggled legal challenges, corporate responsibilities, and raising three kids. Join us as she shares her journey, insightful lessons, and why ethical decision-making is more than just a checklist—sometimes, it's a bit of a balancing act! SHOW NOTES 00:44 Career Journey: From Law to Compliance Leadership 04:33 Creating Impact in Compliance and Ethics 07:32 Emphasising Good Decision-Making Practices 13:01 Navigating Challenges in the Biopharma Industry 22:21 Innovations and Cultural Insights in Global Teams Transcript and more GRC content: https://www.riskywomen.org/2026/02/podcast-s9e5-leading-with-integrity-in-pharma-and-at-home-kim-jablonski/

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making.  Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma.  SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation.  Keep up with the guests;  Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/  John Barry  - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/  Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/  Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/  Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/    Follow Mike Rea On;  Website: https://ideacollider.simplecast.com/  X: https://x.com/ideapharma  LinkedIn: https://www.linkedin.com/in/bigidea/      Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

AI in Pharma Marketing with Nataliya Andreychuk | Pharma Content Strategy, Personalization & Localization #pharmamarketing #aihealthcare #digitalpharmaIn this episode, we talk about how AI is changing pharma marketing and communication. Nataliya Andreychuk, CEO of Viseven, explains how teams use AI to create content that follows rules and connects with doctors and patients. Please visit our website to get more information: https://swangroup.net/ We cover how marketing in pharma is moving from product-focused to useful and relevant messages. Nataliya discusses personalization at scale and how digital tools help make content faster and more accurate. You will hear why data, CRM, and social listening help shape content strategy and how AI helps reduce time for localization and regulatory checks. The episode explains how communication between medical teams and commercial teams is becoming closer with smarter tools. This talk shows how relevant content makes it easier for healthcare professionals and patients to find answers and improve engagement.Links from this episode:✅ Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup ✅ Get to know more about Nataliya Andreychuk: https://www.linkedin.com/in/andreychuk ✅ Learn more about Viseven: https://viseven.com/ ✅ Nataliya's Music Pick:  https://www.youtube.com/watch?v=Vh9sBLXBZII  

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Of the 25 top industries in the country, recent polls now have PHARMA as 24th and the healthcare industry as 23rd, both barely exceeding the federal government at the bottom of the list. The solution to almost all of these issues is always the same- returning to a foundational trust in the eternal truths...

Prefabrication works differently in highly regulated environments. In this episode of Prefab, Unfiltered, recorded live at Advancing Prefabrication, Todd Weyandt sits down with David O'Connell to explore how prefabrication, modular construction, and industrialized strategies perform inside life sciences, pharmaceutical manufacturing, and cleanroom construction. When time to market can mean tens of millions of dollars per day, construction strategy becomes a business-critical decision. But in regulated environments, every weld, inspection, and document must meet strict compliance standards. This conversation unpacks where prefabrication truly adds value in pharma and semiconductor projects, where full modular building approaches struggle, and why regulatory alignment is often the deciding factor. If you are involved in life sciences construction, cleanroom facilities, modular construction, or industrialized project delivery, this episode delivers a grounded and practical perspective.   You'll Learn Why full building modular often struggles in life sciences construction Where prefabrication works best in pharmaceutical and cleanroom environments How regulatory inspections shape prefab strategy Why partnering with agencies having jurisdiction is critical How time to market drives construction decisions in drug manufacturing The financial impact of schedule acceleration in regulated facilities   Meet Our Guest David O'Connell brings decades of experience across semiconductor, life sciences, and pharmaceutical construction. With a background shaped by multiple generations in construction and deep experience delivering highly technical facilities, he has worked at the intersection of prefabrication, regulatory compliance, and time-critical project delivery. His perspective bridges traditional construction methods and modern industrialized strategies, particularly in cleanroom environments and drug manufacturing facilities where documentation, inspection, and compliance are paramount.   Todd Takes Prefabrication Has to Respect Regulation. In pharmaceutical and life sciences construction, compliance is non-negotiable. Prefabrication does not remove regulatory scrutiny. It demands earlier coordination and stronger documentation. Inspectors and agencies must be brought in as partners, not treated as obstacles. Not Everything Should Be Modular. Full building modular has not consistently succeeded in highly regulated environments. Prefabrication often works best in repeatable components such as utility racks, panels, and cleanroom assemblies. Industrialized construction is not all or nothing. Strategic application matters. Time to Market Changes the Equation. In pharmaceutical manufacturing, delayed production can mean millions of dollars per day. That reality shifts the conversation from cost savings to schedule certainty and risk mitigation. Prefabrication becomes a strategic lever for accelerating capacity while maintaining compliance.   More Resources   Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn David's LinkedIn Verista's Website   Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website  

America Out Loud PULSE with Dr. Vaughn & Dr. Tankersley – Of the 25 top industries in the country, recent polls now have PHARMA as 24th and the healthcare industry as 23rd, both barely exceeding the federal government at the bottom of the list. The solution to almost all of these issues is always the same- returning to a foundational trust in the eternal truths...

Pirouette Pharma CEO Conor Cullinane returns to Inside Startup Investing to share the company's progress since its last Wefunder raise—spanning FDA engagement, IND planning, and major steps toward scalable manufacturing. Pirouette is building a disc-shaped, push-button delivery system for injectable medications—aiming to turn the “violent, error-prone” experience of legacy auto-injectors into something closer to the Staples Easy Button: push once, and the device handles the rest. Chris and Conor discuss why intimidation and usability are major barriers in today's injection landscape, how Pirouette is approaching OTC naloxone via a combination-product regulatory pathway, what a pharmacokinetic study looks like, and why Pirouette is investing in manufacturing capacity to support both commercialization and pharma partnerships.   Chapters  00:44 What Pirouette is building 03:42 Progress since last raise 06:26 FDA pathway explained 09:08 PK study + size/cost/timeline 13:07 Partnerships vs. standalone commercialization 16:15 Revenue timing + adoption expectations 20:12 Manufacturing scale plan 23:34 Founder “why” 26:07 Investor close

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My book, Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech is officially out today, and in this special bonus episode, my marketing assistant turns the tables and interviews me about why I wrote this book, how the method came to be, and what I want the reader to feel by the end of it.This isn't a traditional teaching episode. It's more a behind-the-scenes conversation. We talk about the roadblocks I hit in my own 9-to-5, the moment I was told my extra degree and stretch work didn't “count,” and how that experience led me to develop the hidden doors framework.This is honest, unscripted, and be sure to listen to the end to catch the blooper reel.In this episode, you'll learn:The reason I wrote this book — and why I wanted it accessible to every woman in scienceThe story behind “hidden doors” and how roles get created outside the org chartThe career advice I followed early on that slowed me downWhat surprised me most while writing — including what I chose to leave outWhat I hope you feel when you finish the last chapterGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Pharmaceutical packaging is undergoing rapid transformation as connectivity, sustainability, automation, and evolving regulatory demands reshape how medicines are protected, tracked, and delivered. From smart packaging features and prefilled injectables to e-commerce fulfillment and digital compliance systems, packaging and equipment investment decisions are increasingly tied to flexibility, data visibility, and long-term modernization. In this episode of Off Script, we spoke with Rebecca Marquez, director of custom research at PMMI, about the association's latest Trends and Challenges in Pharmaceutical Manufacturing white paper. The conversation explores how connected packaging technologies are strengthening relationships between manufacturers, regulators, and patients; why sustainability initiatives are advancing despite material performance and validation challenges; and how growth in biologics and prefilled injectables is driving new packaging and equipment demands. Marquez also breaks down the regulatory documentation gap between OEMs and end users, the rise of automation technologies, and more.

Can D1 competitive mindset help you dominate the medical sales industry?In this episode of the Medical Sales U Podcast, I sit down with Justin Kershaw—former Michigan State player turned top-tier Spine Endoscopy Rep for Arthrex. Justin pulls back the curtain on how he transitioned from the locker room to the Operating Room, the reality of working for a $5B company like Arthrex, and why being a "Girl Dad" and a man of faith is what actually fuels his professional drive.In this episode, you'll learn: * The "3 Gatekeepers" you must win over to close deals in any hospital.* Why Arthrex uses an "Agency" model vs. traditional distributorships. * How to maintain high-level physical and spiritual discipline in a high-stress career. * Tactical advice for career pivots (how Dave broke into sales at age 35!).

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Pharma Attacks RFK Jr., FDA Moderna Reversal, MAHA Midterm Strategy, Voter ID, Hawaii's Emergency Power Grab, Ari Whitten, Red Light Therapy, Inflammation Reduction, Anhalonium Lewinii, and MORE! https://robertscottbell.com/jonathan-emord-pharma-funded-attacks-on-rfk-jr-fdas-moderna-reversal-maha-midterm-strategy-voter-id-hawaiis-emergency-power-grab-anhalonium-lewinii-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Yes, headlines say U.S. life expectancy has rebounded. But here's what they don't tell you. The United States ranks 32 out of 38 developed nations in life expectancy according to OECD data.Thirty-second. Out of thirty-eight. That places America near the bottom of the developed world behind Turkey, Estonia, the Czech Republic, and the Slovak Republic. Only six developed nations rank lower.At the same time:• In 2024, the 10 largest pharmaceutical companies reported more than $100 billion in profits**• The industry spent over $5 billion on television advertising• Prescription drug commercials account for a significant share of evening news ads• The U.S. healthcare system remains structured around treatment, not prevention• Ultra-processed foods dominate the American dietThe United States spends more per capita on healthcare than any other developed nation.Yet we rank near the bottom in longevity. Americans deserve the complete story — not just the comfortable headline. Source: U.S. Senate Committee on Health, Education, Labor and PensionsThank you to our sponsor: Preserve Gold - text "ASK PHIL" to 50505 and go to https://DrPhilGold.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.